

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



BEIJING TONG REN TANG CHINESE MEDICINE COMPANY LIMITED
北京同仁堂國藥有限公司
(Incorporated in Hong Kong with limited liability)
(Stock Code: 3613)

**RESIGNATION OF
EXECUTIVE DIRECTOR, CHIEF OPERATING OFFICER,
MEMBER OF COMPETITION EXECUTIVE COMMITTEE AND
AUTHORISED REPRESENTATIVE**

**RESIGNATION OF EXECUTIVE DIRECTOR, CHIEF OPERATING OFFICER, MEMBER
OF COMPETITION EXECUTIVE COMMITTEE AND AUTHORISED
REPRESENTATIVE**

The board of directors (the “**Board**”) of Beijing Tong Ren Tang Chinese Medicine Company Limited (the “**Company**”) hereby announces that Ms. Lin Man (“**Ms. Lin**”) has resigned as an executive director, the chief operating officer, member of competition executive committee and authorised representative of the Company (the “**Authorised Representative**”) under Rule 3.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) with effect from 12 September 2023, due to personal endeavours.

Ms. Lin has confirmed that she has no disagreement with the Board or the Company and there is no matter in relation to her resignation that needs to be brought to the attention of shareholders of the Company or The Stock Exchange of Hong Kong Limited.

During her tenure of service at the Company, Ms. Lin faithfully performed her duties and contributed to the Company's development. The Board would like to take this opportunity to express its sincere gratitude to Ms. Lin for her invaluable contribution.

NON-COMPLIANCE WITH LISTING RULES

Following the resignation of Ms. Lin as the Authorised Representative, the Company will not comply with the requirement under Rule 3.05 of the Listing Rules that an issuer should appoint two authorised representatives. The Company will identify a suitable candidate to fill the vacancy of the Authorised Representative as soon as practicable to ensure compliance with Rule 3.05 of the Listing Rules, and will make further announcement as and when appropriate.

By order of the Board
Beijing Tong Ren Tang
Chinese Medicine Company Limited
Chen Fei
Executive Director

Hong Kong, 12 September 2023

As at the date of this announcement, the composition of the Board is as follows:

Executive Director:

Mr. Chen Fei

Non-executive Director:

Ms. Feng Li

Independent Non-executive Directors:

Mr. Tsang Yok Sing, Jasper

Mr. Xu Hong Xi

Mr. Chan Ngai Chi